IVIG for Infection Prevention After CAR-T-Cell Therapy

Condition:   Lymphoma Interventions:   Biological: Immune Globulin Infusion (Human), 10% Solution;   Biological: Anti-CD19-targeting CAR-T Cells;   Other: Saline;   Procedure: Biospecimen Collection;   Other: Survey Administration;   Other: Electronic Health Record Review Sponsors:   Fred Hutchinson Cancer Center;   Takeda;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials